Position in CGC
as of Mar 31, 2026
· filed Apr 13, 2026
Position Value
$3,524
-$707 QoQ
Shares Held
3,714
+0.1% QoQ
Ownership
0.001%
of shares outstanding
% of Portfolio
0.00%
of 13F equity value
Holder Rank
—
not a current holder
Holding Since
Dec 2023
10 quarters on record
Voting authority
Sole 100.ToString("F0")%
Shared 0.ToString("F0")%
None 0.ToString("F0")%
Common Shares in CGC Over Time
Shares Held
Position Value (USD)
Position in Drug Manufacturers - Specialty & Generic
Healthcare · as of Mar 31, 2026IFP Advisors, Inc holds $7,125,146 across 42 Drug Manufacturers - Specialty & Generic names. CGC ranks #25 (0.0% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | TEVA |
Teva Pharmaceutical Industries Ltd
|
142,344 | $4,287,401 | |
| 2 | ZTS |
Zoetis Inc.
|
9,273 | $1,096,161 | |
| 3 | UTHR |
UNITED THERAPEUTICS Corp
|
1,545 | $916,154 | |
| 4 | NBIX |
Neurocrine Biosciences Inc
|
2,792 | $367,818 | |
| 5 | CTOR |
Citius Oncology, Inc.
|
107,424 | $66,602 | |
| 6 | ALKS |
Alkermes plc.
|
1,398 | $49,433 | |
| 7 | HLN |
Haleon plc
|
4,745 | $47,497 | |
| 8 | TLRY |
Tilray Brands, Inc.
|
5,513 | $35,669 |
All Filings in CGC
Export CSV
10 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-03-31 | $3,524 | 3,714 | Shares | Sole | 2026-04-13 | |
| 2025-12-31 | $4,231 | 3,712 | Shares | Sole | 2026-02-06 | |
| 2025-09-30 | $5,400 | 3,699 | Shares | Sole | 2026-02-06 | |
| 2025-06-30 | $2,343 | 1,921 | Shares | Sole | 2025-07-24 | |
| 2025-03-31 | $134 | 148 | Shares | Sole | 2025-05-05 | |
| 2024-12-31 | $550 | 201 | Shares | Sole | 2025-02-04 | |
| 2024-09-30 | $1,229 | 255 | Shares | Sole | 2025-02-04 | |
| 2024-06-30 | $1,128 | 175 | Shares | Sole | 2024-07-30 | |
| 2024-03-31 | $1,708 | 198 | Shares | Sole | 2024-07-30 | |
| 2023-12-31 | $1,011 | 198 | Shares | Sole | 2024-01-09 | |
| No filing history on record for this holder in this stock. | ||||||